Clerkenwell Health

Based in London, UK, and founded in 2020, Clerkenwell Clinics Limited, doing business as Clerkenwell Health, operates as a mental health company that provides psychedelic-specialist CRO (contract research organization) services such as psychedelic-drug clinical trials, and trial management for its clients. The company was co-founded by Thomas Mcdonald (CEO), Sam Lewis (CFO), and Henry Fisher (CSO), and in October 2022, Clerkenwell Health raised GBP 2. 1 million in seed funding from Convergence Partners and Exceptional Ventures, with participation from Lionheart Ventures. The firm offers a wide range of bespoke services including clinical trial design, scientific and regulatory advisory, clinical trial delivery (through a state-of-the-art facility), trial monitoring and management, etc.

, primarily for psychedelic drug manufacturers to help them accelerate the drug development process ranging from phase I to III trials to FDA approval and market launch. The company also conducts clinical trials for any conditions that the clients are interested in studying. Clerkenwell Clinics Limited’s in-house team comprises clinical trial managers, scientists, psychiatric, and psychedelic specialists, etc. The company intends to use the October 2022 funding to make its London facility fully operational.